Thymosin alpha-1 is one of the better examples of why peptide evidence needs to be read in order rather than as a pile of positive findings. The molecule has been studied in people for decades. Some early trials looked encouraging. A larger hepatitis B trial then failed to confirm a clear benefit, and the largest modern sepsis trial found no reduction in mortality. That sequence tells us much more than simply counting how many papers exist.
What is thymosin alpha-1?
Thymosin alpha-1, also called thymalfasin or Tα1, is a 28 amino acid peptide associated with immune regulation. It is different from thymosin beta-4 and from the fragment commonly called TB-500. The shared "thymosin" name reflects history, not interchangeable biology.
The US FDA's compounding review describes thymosin alpha-1 as a peptide with proposed immune modulating effects and discusses activity across dendritic cells, T cells and innate immune signalling Mechanistic 1. Those mechanisms help explain why researchers tested it in chronic viral infection, cancer related immune dysfunction and sepsis.
Mechanism is not the difficult part of this story. The difficult part is deciding whether those immune effects translate into useful clinical outcomes.
Thymosin alpha-1
Mixed evidenceImmune modulation · 6 cited studies
Multiple randomised human trials exist and it holds marketing authorisations for chronic hepatitis B in around 30 countries, but the two largest and most rigorous placebo controlled trials (the 1,106-patient TESTS sepsis trial and the 97-patient phase 3 hepatitis B trial) were both null, and meta analytic benefit disappears when analysis is restricted to high quality multicentre studies.
UK status. No MHRA marketing authorisation.
The early hepatitis B story looked promising
One of the earliest placebo controlled human studies included just 12 people with chronic hepatitis B. Seven received thymosin treatment and five received placebo. By the end of the study, six of the seven thymosin treated participants had cleared detectable hepatitis B virus DNA from serum compared with one of five in the placebo group Human 2.
That is a striking proportion, but twelve people is far too small to settle efficacy. Small studies can produce large apparent effects by chance, and early studies often include highly selected patients. The proper response to a result like that is a larger controlled trial.
A phase 3 multicentre double blind placebo controlled trial published in 1999 did exactly that. It enrolled 97 people with HBeAg positive, HBV DNA positive chronic hepatitis B. Forty nine received thymosin alpha-1 and 48 received placebo for six months, followed by another six months of observation Human 3.
The complete response rate was 14% with thymosin alpha-1 and 4% with placebo. The difference did not reach statistical significance. The published abstract reports a P value of 0.084. Sustained loss of HBV DNA was also numerically higher with thymosin alpha-1, but the authors concluded that the trial did not confirm the treatment efficacy reported in earlier clinical studies.
This is the first major lesson from the thymosin alpha-1 record. A small study can produce a strong looking signal, while a larger and better controlled trial can make that signal look much less certain.
Sepsis followed almost the same pattern
The sepsis programme is even more informative because it contains an earlier positive leaning trial followed by a much larger modern phase 3 test.
The 2013 ETASS trial randomised 361 people with severe sepsis across six hospitals in China. Participants received standard care with or without thymosin alpha-1. At 28 days, mortality was 26.0% in the thymosin alpha-1 group and 35.0% in the control group Human 4.
That result looked promising, but the statistical picture was borderline. The reported relative risk was 0.74 with a 95% confidence interval from 0.54 to 1.02. The unstratified P value was 0.062, while the log rank comparison was 0.049. The trial also reported changes in an immune marker called monocyte HLA-DR.
Those findings were enough to justify a stronger test. They were not enough to prove that thymosin alpha-1 reduces sepsis mortality.
The 1,106 person TESTS trial was negative
The TESTS trial, published in the BMJ in 2025, was designed to answer the question much more decisively. It enrolled 1,106 adults with sepsis across 22 centres in China and randomly assigned 552 to thymosin alpha-1 and 554 to placebo. Treatment was given by subcutaneous injection every 12 hours for seven days, unless stopped earlier because of intensive care discharge, death or withdrawal Human 5.
The primary outcome was 28 day all cause mortality. In the modified intention to treat analysis, 23.4% of participants receiving thymosin alpha-1 died within 28 days compared with 24.1% receiving placebo. The current BMJ report gives a hazard ratio of 0.97, with a 95% confidence interval from 0.76 to 1.24 and a P value of 0.82 Human 6.
That is not a near miss. The groups were very close.
The trial also found no significant difference in 90 day mortality. The published report says no secondary or safety outcome differed significantly between the groups. The most direct reading is that thymosin alpha-1 did not reduce mortality in the population studied.
This later result matters more than the earlier ETASS signal because TESTS was larger, double blind and placebo controlled. It was built to reduce the kinds of bias and random variation that can make smaller studies look more impressive than they really are.
Does that mean thymosin alpha-1 does nothing?
No. A negative sepsis trial does not prove that the molecule has no biological activity, and it does not erase every earlier clinical observation. It does tell us that biological activity and improvement in immune markers did not translate into lower mortality in the largest sepsis trial.
That distinction is central to peptide science. A treatment can alter a pathway, change a laboratory marker or influence immune cells without producing the clinical outcome that matters to patients.
The same principle applies to hepatitis B. Earlier work showed antiviral and immune signals. The larger phase 3 trial still failed to show a statistically convincing complete response advantage over placebo.
A fair evidence summary therefore sits between two extremes. Calling thymosin alpha-1 "unresearched" would be wrong. Calling it a proven general immune enhancer would also be wrong.
What about the idea of "immune optimisation"?
This is where the online story moves beyond the clinical record. The major human studies were conducted in people with serious medical conditions such as chronic hepatitis B or sepsis. They were not trials of healthy adults trying to improve resilience, energy, recovery or general immune function.
That gap matters. Evidence from critically ill or chronically infected patients cannot simply be transferred to healthy people. The immune system is context dependent. A signal in severe infection does not establish a benefit from administering the same compound to someone without that illness.
No large randomised trial has established that thymosin alpha-1 improves health, prevents routine infections or produces a meaningful wellness benefit in otherwise healthy adults.
What do we know about safety?
Thymosin alpha-1 has more human safety exposure than many research peptides. In the 2025 TESTS trial, more than 500 participants received thymosin alpha-1 and the investigators reported no significant difference in safety outcomes compared with placebo Human 5.
That is useful evidence, but it has limits. TESTS involved a short treatment period in critically ill patients under hospital supervision. The hepatitis studies also involved defined clinical populations and controlled treatment periods. These trials do not establish the safety of repeated unsupervised use in healthy people over months or years.
The FDA's current compounding safety page also separates the known clinical record from concerns about compounded material. It says compounded thymosin alpha-1 may present immunogenicity risk for some routes and raises concerns about peptide related impurities and characterisation of the active ingredient 7.
That is a product quality problem as much as a molecule problem. A clinical trial using a defined pharmaceutical preparation is not evidence that an unrelated vial from an unregulated supply chain has the same identity, purity or sterility.
Is thymosin alpha-1 FDA approved?
No. FDA's December 2024 compounding briefing states that the agency had approved no drug products containing thymosin alpha-1 1.
At the same meeting, the Pharmacy Compounding Advisory Committee voted against recommending thymosin alpha-1 free base and thymosin alpha-1 acetate for inclusion on the section 503A Bulks List. A later federal advisory committee report recorded the vote as 4 yes to 17 no 8.
That compounding decision is not the same thing as a drug approval decision. It does, however, show that the existence of published human trials should not be confused with FDA approval.
What does the UK position mean?
UK medicines are regulated separately. The MHRA states that a medicine needs a UK marketing authorisation before it can be marketed as an authorised medicine in the UK, and applications are submitted through the MHRA process 9.
Approval or clinical use in another country does not automatically create a UK authorisation. Readers checking any medicine should use the MHRA product information service for the current licence record rather than assume that foreign status carries across 10.
Why the evidence hierarchy changes the answer
Thymosin alpha-1 is a useful case study in why larger trials matter. The early hepatitis pilot study looked strong. The later phase 3 hepatitis trial was much less convincing. ETASS suggested lower sepsis mortality. TESTS, with more than a thousand randomised participants and stronger blinding, found no mortality benefit.
If you only collect the positive papers, you can make the compound look highly effective. If you only quote the negative papers, you lose the fact that there is real human biology and a long clinical research history. The evidence based answer is more specific: thymosin alpha-1 has genuine human trial data, but its strongest modern studies do not support the broad efficacy claims often made online.
That is also why BioRx separates evidence tiers. The number of papers matters less than the design, size, population and outcome of the best studies.
Frequently asked questions
Is thymosin alpha-1 the same as TB-500?
No. Thymosin alpha-1 and thymosin beta-4 are different peptides with different biology. TB-500 is discussed as a fragment related to thymosin beta-4, while thymosin alpha-1 is an immune modulating peptide. Sharing the word "thymosin" does not make them interchangeable.
Did thymosin alpha-1 reduce deaths in sepsis?
The largest and strongest trial did not. In TESTS, 28 day mortality was 23.4% with thymosin alpha-1 and 24.1% with placebo Human 5. The earlier ETASS study reported a more favourable signal, but the later phase 3 result did not confirm it.
Does thymosin alpha-1 have human research?
Yes. It has decades of human studies, including randomised controlled trials in chronic hepatitis B and sepsis. That makes it better studied than many peptides discussed online. The existence of human research does not mean every claimed use has been proven.
Is thymosin alpha-1 FDA approved?
No. FDA's own compounding briefing states that no FDA approved drug product contains thymosin alpha-1 1.
Does thymosin alpha-1 boost the immune system in healthy people?
That has not been established in a large randomised clinical trial. The best known human studies involve people with serious illnesses, so they cannot be used as proof of a general wellness effect in healthy adults.
References
Studies marked "View study in BioRx" sit in the clinical studies index with their design and evidence grade.
- FDA Pharmacy Compounding Advisory Committee briefing on thymosin alpha-1, December 2024
- Mutchnick et al., placebo controlled pilot trial in chronic hepatitis B, PMID 1874487
- Mutchnick MG, et al. (1999). Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. Journal of Viral Hepatitis.PubMed · DOI · View study in BioRx
- Wu J, et al. (2013). The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Critical Care.PubMed · DOI · ClinicalTrials.gov · View study in BioRx
- Wu J, et al. (2025). The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial. BMJ.PubMed · DOI · ClinicalTrials.gov · View study in BioRx
- BMJ TESTS trial, 15 January 2025
- FDA, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
- US federal advisory committee report for the Pharmacy Compounding Advisory Committee, FY2025
- MHRA, apply for a licence to market a medicine in the UK
- MHRA, find product information about medicines
